Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Accumulated Expenses (2021 - 2025)

Rxo (RXO) has disclosed Accumulated Expenses for 5 consecutive years, with $397.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 6.43% year-over-year to $397.0 million, compared with a TTM value of $397.0 million through Dec 2025, up 6.43%, and an annual FY2025 reading of $397.0 million, up 6.43% over the prior year.
  • Accumulated Expenses was $397.0 million for Q4 2025 at Rxo, up from $321.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $397.0 million in Q4 2025 and bottomed at $197.0 million in Q2 2024.
  • Average Accumulated Expenses over 5 years is $275.1 million, with a median of $262.0 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses fell 22.27% in 2023, then soared 87.44% in 2024.
  • Year by year, Accumulated Expenses stood at $248.0 million in 2021, then grew by 3.23% to $256.0 million in 2022, then dropped by 22.27% to $199.0 million in 2023, then skyrocketed by 87.44% to $373.0 million in 2024, then rose by 6.43% to $397.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for RXO at $397.0 million in Q4 2025, $321.0 million in Q3 2025, and $315.0 million in Q2 2025.